RE:RE:RE:Nice buy-backs !!!!gudisgood wrote: EbbFlow88 wrote: The volume has been good the last couple days. I'm sure they've been buying even more. Excited for earnings this week!
We're steady approaching 115 million outstanding shares. If the shares are undervalued -- which I certainly believe them to be, and Goodman/Samira seem to agree -- they keep adding value to shareholders (potentially significant value!) with this extremely simple action.
At the same time, I do hope they find other productive uses for the money soon. Whenever they spend on money share buybacks, it means that's the best use of money they can think of. It's great to take an advantage of the share price... but it would be even nicer if they had better opportunities. :)
Exactly - buybacks are the quickest and easiest way for them to help shareholders right now - to prepare for the time when shareholders find Knight in favor.
They do have expectations to use the shelf prospectus but only if it's at higher valuation than the last deal. No green light to use the shelf prospectus unless we're above the $12-$15 range (IMO).
Focus is likely on selling our present wares and EXELON is at the top of that list. Lots of potential on the selling side. I am assuming Knight is trying to prove to Novartis that they are the partner of choice in LATAM - side game going on here.
At this time, the most likely acquisitions will be small - individual drugs, until the timing and price is right for something bigger. We have enough cash and cashflow coming for small acquisitions while we focus on the art of selling ... and ... continue to whittle down the share count. That also buys time as they develop the branded generics portfolio. The options and directions are growing - the more tools they have, the merrier it will be for this company in the future.
It is obviouls that the base is so much bigger and so much stronger than what they created the first time. It's just slow - a drug licensing characteristic (in the early years) that you are not going to escape (like gravity).